APP and Alzheimer disease: Similarly, another study has shown that delivering microRNA agomirs, which can increase CPE expression, via intracerebroventricular injection or intranasal instillation in the APP/PS1 mouse model also led to significant improvements in the same neuropathological hallmarks of AD 32.